Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	10.95B
Revenue (ttm)	668.43M
Net Income (ttm)	61.90M
Shares Out	405.93M
EPS (ttm)	0.15
PE Ratio	176.46
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,351,430
Average Volume	9,666,612
Open	26.76
Previous Close	26.97
Day's Range	26.63 - 28.75
52-Week Range	8.11 - 34.68
Beta	0.67
RSI	49.92
Earnings Date	Aug 29, 2025

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and staphylococcus aureus, which is in Phase 3 clinical trial. In addition, it engages in technology promotion and application services business; biotechnology, R&D, and consulting. The company was founded...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 470
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2024, SHA:688319's revenue was 588.86 million, an increase of 18.69% compared to the previous year's 496.12 million. Earnings were 20.76 million, an increase of 18.24%.